Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with multiple myeloma (MM) who have a confirmed diagnosis, need treatment, and whose disease has come back or stopped responding after at least 3 previous rounds of treatment.
- People with non-Hodgkin's lymphoma (NHL) whose disease has come back or stopped responding after at least 2 previous rounds of chemotherapy.
- People who are largely able to carry out daily activities with little or no limitation (rated 0 or 1 on a standard activity scale used by doctors).
- People whose doctor estimates they are expected to live for more than 12 weeks.
Who may not be able to join:
- People who have significant heart problems or a history of serious heart disease.
- People who have HIV, active hepatitis B, or hepatitis C infection.
- People who currently have an active COVID-19 (SARS-CoV-2) infection.
- People who have untreated cancer that has spread to the brain or the area around the spinal cord.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1); Incidence of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1); Nature of dose-limiting toxicities (DLTs) of IDP-023 Monotherapy - (Phase 1); Incidence of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1); Nature of dose-limiting toxicities (DLTs) of IDP-023 in combination with Isatuximab, Daratumumab or Rituximab - (Phase 1); Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1); For MM: Anti-tumor activity by objectiv...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.